Rich Erickson

591 total citations
18 papers, 319 citations indexed

About

Rich Erickson is a scholar working on Immunology, Genetics and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Rich Erickson has authored 18 papers receiving a total of 319 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Immunology, 7 papers in Genetics and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Rich Erickson's work include Inflammatory Bowel Disease (6 papers), Biosimilars and Bioanalytical Methods (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Rich Erickson is often cited by papers focused on Inflammatory Bowel Disease (6 papers), Biosimilars and Bioanalytical Methods (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Rich Erickson collaborates with scholars based in United States, United Kingdom and Switzerland. Rich Erickson's co-authors include Dimitry M. Danilenko, Daniel E. Waite, Eric Stefanich, Yehong Wang, John T. Curnutte, Julie Rae, Deborah Noack, Jiabing Ding, Pablo Javier Patiño Grajales and Franklin Fuh and has published in prestigious journals such as Blood, Biochemical Journal and Journal of Allergy and Clinical Immunology.

In The Last Decade

Rich Erickson

17 papers receiving 296 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rich Erickson United States 9 133 103 69 68 57 18 319
Angela Barone Sweden 12 112 0.8× 161 1.6× 67 1.0× 42 0.6× 18 0.3× 20 407
Oppenheim Jj United States 9 152 1.1× 49 0.5× 68 1.0× 20 0.3× 42 0.7× 18 327
T. C. Alford United States 9 157 1.2× 86 0.8× 152 2.2× 103 1.5× 46 0.8× 20 453
Hari Nadiminti United States 8 100 0.8× 95 0.9× 121 1.8× 29 0.4× 10 0.2× 15 358
Carina Kärrman Mårdh Sweden 8 137 1.0× 228 2.2× 61 0.9× 85 1.3× 4 0.1× 9 446
Mirjana Urosevic‐Maiwald Switzerland 12 264 2.0× 139 1.3× 190 2.8× 21 0.3× 16 0.3× 24 583
Daniela Olivero Italy 11 24 0.2× 141 1.4× 62 0.9× 58 0.9× 12 0.2× 20 467
Hideshi Kumai Japan 7 45 0.3× 189 1.8× 73 1.1× 37 0.5× 14 0.2× 9 330
Jacqueline Turton Australia 6 84 0.6× 156 1.5× 80 1.2× 54 0.8× 18 0.3× 6 371
R L Moy United States 6 270 2.0× 66 0.6× 178 2.6× 18 0.3× 23 0.4× 7 482

Countries citing papers authored by Rich Erickson

Since Specialization
Citations

This map shows the geographic impact of Rich Erickson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rich Erickson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rich Erickson more than expected).

Fields of papers citing papers by Rich Erickson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rich Erickson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rich Erickson. The network helps show where Rich Erickson may publish in the future.

Co-authorship network of co-authors of Rich Erickson

This figure shows the co-authorship network connecting the top 25 collaborators of Rich Erickson. A scholar is included among the top collaborators of Rich Erickson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rich Erickson. Rich Erickson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Zhang, Wenhui, Helen E.J. Tyrrell, Han Ting Ding, et al.. (2021). Comparable Pharmacokinetics, Safety, and Tolerability of Etrolizumab Administered by Prefilled Syringe or Autoinjector in a Randomized Trial in Healthy Volunteers. Advances in Therapy. 38(5). 2418–2434. 2 indexed citations
2.
Becker, Emily, Franklin Fuh, Philipp Tripal, et al.. (2019). Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease. Frontiers in Pharmacology. 10. 39–39. 31 indexed citations
3.
Tang, Meina, Mary Keir, Rich Erickson, et al.. (2018). Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti‐β7 integrin therapy for inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 47(11). 1440–1452. 26 indexed citations
4.
5.
Rothenberg, Michael E., Yehong Wang, Annemarie Lekkerkerker, et al.. (2018). Randomized Phase I Healthy Volunteer Study of UTTR1147A (IL‐22Fc): A Potential Therapy for Epithelial Injury. Clinical Pharmacology & Therapeutics. 105(1). 177–189. 53 indexed citations
6.
Cai, Fang, Francis Abreu, Han Ting Ding, et al.. (2018). Nasal Biomarkers Characterization In Lebrikizumab Bronchoscopy Study (CLAVIER). Journal of Allergy and Clinical Immunology. 141(2). AB118–AB118. 2 indexed citations
7.
Wei, Xiaohui, Leonid Gibiansky, Yehong Wang, et al.. (2017). Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis. The Journal of Clinical Pharmacology. 58(3). 386–398. 6 indexed citations
8.
Williams, Kathi, Rich Erickson, & Saloumeh K Fischer. (2017). Overcoming Disease-Specific Matrix Effect in A Clinical Pharmacokinetic Assay Using A Microfluidic Immunoassay Technology. Bioanalysis. 9(16). 1207–1216. 8 indexed citations
9.
Fuh, Franklin, Rich Erickson, Romeo Maciuca, et al.. (2015). Etrolizumab Treatment Does Not Modify Levels of VCAM-1 in Ulcerative Colitis Patients. The American Journal of Gastroenterology. 110. S797–S798. 1 indexed citations
10.
Fuh, Franklin, Rich Erickson, Meina Tang, et al.. (2015). Etrolizumab Treatment Modulates MAdCAM-1 Levels in Serum in Ulcerative Colitis Patients. The American Journal of Gastroenterology. 110. S797–S797. 3 indexed citations
11.
Peng, Kun, Keyang Xu, Luna Liu, et al.. (2014). Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study. mAbs. 6(6). 1500–1508. 8 indexed citations
12.
Wei, Xiaohui, Diana Luca, Yehong Wang, et al.. (2014). Etrolizumab Population Pharmacokinetics (Pop PK) and Covariate Analysis in Patients With Moderately to Severely Active Ulcerative Colitis (UC). The American Journal of Gastroenterology. 109. S496–S496. 3 indexed citations
13.
Cowan, Kyra J., Rich Erickson, Bert Gunter, et al.. (2012). Utilizing Design of Experiments to Characterize Assay Robustness. Bioanalysis. 4(17). 2127–2139. 4 indexed citations
14.
Strickland, Laura A, Jed Ross, Simon A. Williams, et al.. (2009). Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma. The Journal of Pathology. 218(3). 380–390. 51 indexed citations
15.
16.
Byrd, J C, Derek T. A. Lamport, Bader Siddiqui, et al.. (1989). Deglycosylation of mucin from LS174T colon cancer cells by hydrogen fluoride treatment. Biochemical Journal. 261(2). 617–625. 25 indexed citations
17.
Erickson, Rich, et al.. (1962). Minor salivary gland sialolithiasis. Oral Surgery Oral Medicine Oral Pathology. 15(2). 200–202. 16 indexed citations
18.
Erickson, Rich, et al.. (1960). A study of dry sockets. Oral Surgery Oral Medicine Oral Pathology. 13(9). 1046–1050. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Angela Barone Breakdown of academic impact, for papers by Oppenheim Jj Breakdown of academic impact, for papers by T. C. Alford Breakdown of academic impact, for papers by Hari Nadiminti Breakdown of academic impact, for papers by Carina Kärrman Mårdh Breakdown of academic impact, for papers by Mirjana Urosevic‐Maiwald Breakdown of academic impact, for papers by Daniela Olivero Breakdown of academic impact, for papers by Hideshi Kumai Breakdown of academic impact, for papers by Jacqueline Turton Breakdown of academic impact, for papers by R L Moy
Rankless by CCL
2026